Group 1 - The core point of the article is that Fuan Pharmaceutical (300194.SZ) has announced that, apart from original research import manufacturers, Qingyutang is the first generic manufacturer of cefotetan granules in China [1] Group 2 - Fuan Pharmaceutical made this announcement on its investor interaction platform [1] - The mention of Qingyutang as the first generic manufacturer indicates a competitive landscape in the pharmaceutical industry, particularly in the area of cefotetan granules [1] - This development may have implications for market dynamics and pricing strategies within the pharmaceutical sector in China [1]

（文章来源：证券日报） 证券日报网讯 12月1日晚间，福安药业发布公告称，全资子公司福安药业集团庆余堂制药有限公司于近 日收到国家药品监督管理局签发的头孢托仑匹酯颗粒（50mg、30mg）药品注册证书，国药准字 H20256029、H20256028，经审查本品符合药品注册的有关要求，批准注册，发给药品注册证书。 ...

Group 1: SAIC Motor Corporation - In November, SAIC Motor's total vehicle sales reached 460,800 units, a year-on-year decrease of 3.75% [1] - New energy vehicle sales were 209,400 units, showing a year-on-year increase of 19.75% [1] - Cumulative vehicle sales from January to November reached 4,108,100 units, a year-on-year increase of 16.38% [1] - SAIC's subsidiary plans to establish a private equity fund focused on the smart electric vehicle industry with an initial subscription size of 1.09 billion yuan [1] Group 2: Top Group - Top Group is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - The company is in discussions with relevant intermediaries regarding the specifics of the H-share listing [2] Group 3: Ningbo Fuda - Ningbo Fuda's subsidiary intends to publicly sell 100% equity of its subsidiary, Hekou Yingzhou Cement Company, with an assessed value of 1.5752 million yuan [4] Group 4: Fuguang Co., Ltd. - Fuguang Co., Ltd. plans to sell a 25% stake in its associate company, Xiaotunpai, for 67.2636 million yuan [5] Group 5: Puluo Pharmaceutical - Puluo Pharmaceutical's subsidiary received a drug registration certificate for Amoxicillin and Clavulanate Potassium Tablets, used for various infections [6][7] Group 6: Fosun Pharma - Fosun Pharma's subsidiary received approval to conduct Phase I clinical trials for a dual-specific antibody injection for treating advanced solid tumors [8] Group 7: Far East Group - Far East Group's subsidiaries won contracts totaling 2.383 billion yuan in November [9] Group 8: Samsung Medical - Samsung Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 124 million yuan [10] Group 9: Changhua Group - Changhua Group received a development notification from a domestic automaker, with an expected total sales amount of approximately 732 million yuan over five years [12] Group 10: Xinbang Intelligent - Xinbang Intelligent's application for issuing shares to acquire Wuxi Yindichip Microelectronics has been accepted by the Shenzhen Stock Exchange [14] Group 11: Jinjing Development - Jinjing Development's subsidiary won a residential and commercial land bid in Tianjin for 474 million yuan [16] Group 12: Guohong Holdings - Guohong Holdings signed an investment framework agreement to develop a strategic emerging industry park in Tanzhou Town [17] Group 13: Hanma Technology - Hanma Technology reported a 149.94% year-on-year increase in truck sales in November, totaling 2,002 units [22] Group 14: Yufeng Group - Yufeng Group decided to terminate its plan to issue A-shares due to the expiration of authorization and market conditions [24] Group 15: Zhenhua Electric - Zhenhua Electric's subsidiary plans to invest up to 201 million yuan in a private equity fund focused on specific industries, including new energy [28] Group 16: Fuao Co., Ltd. - Fuao Co., Ltd. completed the transfer of 40% equity in Fuao Wan'an for 26.222 million yuan [29] Group 17: Baotailong - Baotailong plans to acquire an additional 2.83% stake in its subsidiary, totaling 15 million yuan [31] Group 18: Zhongchao Holdings - Zhongchao Holdings' subsidiaries won projects totaling 1.318 billion yuan [32] Group 19: Annie Co., Ltd. - Annie Co., Ltd. announced a potential change in control, leading to a temporary suspension of its stock [34] Group 20: Ganfeng Lithium - Ganfeng Lithium's subsidiary plans to issue $100 million in exchangeable notes [38]

Core Viewpoint - The company Fu'an Pharmaceutical (300194) has obtained invention patents related to the crystal forms and preparation methods of its psychiatric drugs Butorphanol and Midazolam, but has not yet secured patents for the related compositions [1] Group 1 - The company has responded to investor inquiries on an interactive platform regarding its patent status [1] - The patents obtained are specifically for the crystal forms and preparation methods of Butorphanol and Midazolam [1] - There is currently no patent for the related compositions of these drugs [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for "Cefotaxime Granules," which is indicated for various infections caused by sensitive bacteria [1] Company Summary - Fuan Pharmaceutical's subsidiary, Qingyutang, is now authorized to market Cefotaxime Granules, expanding its product portfolio [1] - The drug is suitable for treating superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory and urinary tract infections [1] - Currently, there are two companies, including Qingyutang, that have passed the consistency evaluation for this drug [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for "Cefotaxime Granules," which is indicated for various infections caused by sensitive bacteria [1] Company Summary - Fuan Pharmaceutical's subsidiary, Qingyutang, is now authorized to market Cefotaxime Granules, expanding its product portfolio [1] - The drug is suitable for treating superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory and urinary tract infections [1] - Currently, there are two companies, including Qingyutang, that have passed the consistency evaluation for this drug [1] Industry Summary - The approval of Cefotaxime Granules reflects ongoing regulatory support for new pharmaceutical products in the market [1] - The drug addresses a wide range of bacterial infections, indicating a potential growth area in the pharmaceutical industry [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang, has received a drug registration certificate from the National Medical Products Administration for its product, Cefotolan Pivoxil Granules, indicating a significant regulatory milestone for the company [1] Group 1: Product Information - Cefotolan Pivoxil Granules are indicated for a variety of infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and secondary infections from trauma, burns, and surgical wounds [1] - The drug is also applicable for treating perianal abscesses, pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscesses, chronic respiratory system diseases, otitis media, sinusitis, periodontitis, jaw inflammation, cystitis, pyelonephritis, scarlet fever, and whooping cough [1]

格隆汇12月1日丨福安药业(300194.SZ)公布，全资子公司福安药业集团庆余堂制药有限公司（简称"庆 余堂"）于近日收到国家药品监督管理局签发的药品注册证书，药品名称：头孢托仑匹酯颗粒。头孢托 仑匹酯颗粒适用于敏感菌引起的浅表性皮肤感染、深部皮肤感染、淋巴管及淋巴结炎、慢性脓皮病、外 伤、烫伤以及手术创口等的继发性感染、肛周脓肿、咽炎及喉炎、扁桃体炎、急性支气管炎、肺炎、肺 脓肿、慢性呼吸系统病变的继发性感染、中耳炎、鼻窦炎、牙周炎、颌炎、膀胱炎、肾盂肾炎、猩红 热、百日咳。 ...

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of Fu'an Pharmaceutical, Qingyutang, has received a drug registration certificate from the National Medical Products Administration for a new product, which is expected to enhance the company's product line and market competitiveness [1] Group 1: Product Registration - The drug name is Cefotaxime Sodium Granules, classified as a Category 4 chemical drug, with specifications of 50mg and 30mg [1] - The approval numbers for the drug are National Drug Approval Code H20256029 and H20256028 [1] - Currently, only two companies have passed the consistency evaluation or are deemed to have passed it for this drug [1] Group 2: Market Impact - The acquisition of the drug registration certificate will enrich the subsidiary's product line and improve its market competitiveness [1] - However, the production and sales situation of the product, as well as its specific impact on the company's performance, remain uncertain due to industry policies and market environment changes [1]

证券代码：300194 证券简称：福安药业 公告编号：2025-042 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 二〇二五年十二月一日 | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | | 头孢托仑匹酯 | 化药 4 | 类 | 50mg | 庆余堂 | 国药准字 H20256029 国药准字 | 经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。 | | 颗粒 | | | | | | | | | | | 30mg | | H20256028 | | 头孢托仑匹酯颗粒适用于敏感菌引起的浅表性皮肤感染、深部皮肤感染、淋 巴管及淋巴结炎、慢性脓皮病、外伤、烫伤以及手术创口等的继发性感染、肛周 脓肿、咽炎及喉炎、扁桃体炎、急性支气管炎、肺炎、肺脓肿、慢性呼吸系统病 变的继发性感染、中耳炎、鼻窦炎、牙周炎、颌炎、膀胱炎、肾盂肾炎、猩红热、 百日 ...